Surashree Kulkarni - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Surashree Kulkarni

Manager - Application Sciences Bio-Techne Corporation

Seminars

Wednesday 14th October 2026

Leveraging Automated CE Technologies to Accelerate ADC Development & Characterization: From Discovery to QC Release

11:30 am

Evaluating ADC-Induced DNA damage and cell death with Simple Western system
Characterizing ADC mechanism of action and target engagement with Simple Western system
Breaking down characterization of ADC critical quality attributes with MauriceFlex

_Surashree Kulkarni - Speaker at 17th World ADC San Diego Summit

View all Speakers

View Event Brochure